Activity of grepafloxacin and other fluoroquinones and newer macrolides against recent clinical isolates of Chlamydia pneumoniae

International Journal of Antimicrobial Agents

Volumn 12, Issue 2, 1999, Pages 181-184

  Roblin, Patricia M ^a   Kutlin, Andrei ^a   Reznik, Tamara ^a   Hammerschlag, Margaret R ^a  

^a Departments of Obstetrics   (United States)

Author keywords

Chlamydia pneumoniae; Grepafloxacin; Quinolones

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; GREPAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; CHLAMYDOPHILA PNEUMONIAE; IN VITRO STUDY; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION;

ADULT; ANTI-INFECTIVE AGENTS; CELL LINE; CHLAMYDOPHILA PNEUMONIAE; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; PIPERAZINES;

EID: 0032998076     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(99)00057-6     Document Type: Article

References (22)

1. Grayston J.T., Campbell L.A., Kuo C.-C. et al. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis. 161:1990;618-625.
2. Block S., Hedrick J., Hammerschlag M.R., Cassell G.H., Craft J.C. Mycoplasma pneumoniae and Chlamydia pneumoniae in community-acquired pneumonia in children: Comparative safety and efficacy of clarithromycin and erythromycin suspensions. Pediatr Infect Dis J. 14:1995;471-477.
3. Maskell J.P., Whiley A.C., Sefton A.M. In vitro activity of grepafloxacin against Haemophilus influenzae and Moraxella catarrhalis. Eur J Clin Microbiol Infect Dis. 17:1998;293-295.
4. Barry A.L., Fuchs P.C. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin. J Chemother. 9:1997;9-16.
5. Ridgway G.L., Salman H., Robbins M.J. et al. The in vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp. J Antimicrob Chemother. 40(Suppl A):1997;31-34.
6. Hammerschlag M.R., Hyman C.L., Roblin P.M. In vitro activities of five quinolones against Chlamydia pneumoniae. Antimicrob Agents Chemother. 36:1992;682-683.
7. Hammerschlag M.R., Qumei K.K., Roblin P.M. In vitro activity of azithromycin, clarithromycin, L-ofloxacin and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother. 36:1992;1573-1574.
8. Roblin P.M., Montalban G., Hammerschlag M.R. In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae. Antimicrob Agents Chemother. 38:1994;1402-1403.
9. Roblin P.M., Kutlin A., Hammerschlag M.R. In vitro activity of trovafloxacin against Chlamydia pneumoniae. Antimicrob Agents Chemother. 41:1997;2033-2034.
10. Roblin P.M., Hammerschlag M.R. In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae. Antimicrob Agents Chemother. 42:1998;951-952.
11. Kimura M., Kishimoto T., Niki Y., Soejima R. In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents. Antimicrob Agents Chemother. 37:1993;801-803.
12. Wise R., Andrews J.M., Brenwald N. The in vitro activity of OPC-17116, a new 5-methyl substituted quinolone. J Antimicrob Chemother. 31:1993;497-504.
13. Roblin P.M., Dumornay W., Hammerschlag M.R. Use of HEp-2 cells for improved isolation and passage of Chlamydia pneumoniae. J Clin Microbiol. 30:1992;1968-1971.
14. Lipsky B.A., Tack K.J., Kuo C.-C., Wang S.P., Grayston J.T. Ofloxacin treatment of Chlamydia pneumoniae (Strain TWAR) lower respiratory tract infections. Am J Med. 89:1990;722-724.
15. File T.M., Segreti J., Dunbar L. et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in the treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother. 41:1997;1965-1972.
16. Leophonte P., Baldwin R.J.T., Pluck N. Trovafloxacin versus amoxicillin/clavulanic acid in the treatment of acute exacerbations of chronic obstructive bronchitis. Eur J Clin Microbiol Infect Dis. 17:1998;434-440.
17. Deabate C.A., Henry D., Bensch G. et al. Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis - a multicenter, double-blind, randomized, comparative study. Chest. 114:1998;120-130.
18. Chodosh S., Lakshminarayan S., Swarz H. et al. Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily. Antimicrob Agents Chemother. 42:1998;114-120.
19. Langan C.E., Cranfield R., Breisch S. et al. Randomized, double-blind study of grepafloxacin vs amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother. 40(Suppl A):1997;63-72.
20. Topkis S, Swarz H, Breisch S.A. et al. Efficacy and safety of grepafloxacin 600 mg daily for 10 days in patients with community-acquired pneumonia. Clin Ther. 5:1997;975-988.
21. O'Doherty B., Dutchman D.A., Pettit R. et al. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patient with community-acquired pneumonia. J Antimicrob Chemother. 40(Suppl 1):1997;73-81.
22. Cook P.J., Andrews J.M., Wise R., Honeybourne D., Moudgil H. Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments. J Antimicrob Chemother. 35:1995;317-326.